Vemurafenib resistance management

Approximately40% to 60% of melanomas have BRAF mutations. Selective BRAF inhibitors such as vemurafenib and dabrafenib are currently approved to treat patients with BRAF-mutated advanced melanoma. Treatment-induced tumor regression occurs in most patients; however, acquired resistance to BRAF inhibitors is observed in most patients after 6-7 months. After disease progression, patients may be treated with ipilimumab followed by chemotherapy. Subsequent systemic treatment options for patients with metastatic melanoma do not exist.

Standard treatment with vemurafenib involves taking the drug by mouth daily until disease progression. ,In second-line treatment, patients may receiveipilimumab followed by chemotherapy. Follow-up systemic treatment options outside of clinical trials do not exist, and patients with metastatic melanoma who do well are left without treatment. In patients in clinical studies, a rapid decrease in lactate dehydrogenase (LDH) (after 1 week) and resolution of cutaneous metastases (after 2 weeks) were observed after re-treatment with vemurafenib. A rapid decrease in LDH indicates that the patient has previously responded to treatment. If a patient develops drug resistance after taking vemurafenib, the doctor should be informed promptly.

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.